InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingGlobeNewsWire • 03/07/25
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingGlobeNewsWire • 02/28/25
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor ConferencesGlobeNewsWire • 02/25/25
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 02/18/25
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 02/14/25
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)GlobeNewsWire • 01/15/25
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904GlobeNewsWire • 12/20/24
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress SyndromeGlobeNewsWire • 11/15/24
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/08/24
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology CongressGlobeNewsWire • 09/25/24
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human DiseasesGlobeNewsWire • 09/03/24
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/24
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)GlobeNewsWire • 06/24/24
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsGlobeNewsWire • 05/21/24
InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/24
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventGlobeNewsWire • 04/24/24